What does peptide mapping catch that mass spectrometry alone misses?

I have the report as a PDF with the chromatogram on page two, so I can quote specifics.

The comparison I want does not seem to exist anywhere in a form I can evaluate.

I have read the arguments for each and they do not engage with each other.

What does each option buy me, and what does it cost me?

Answer first: peptide mapping is the test that earns its cost exactly when mass spectrometry on the intact molecule is uninformative, which is more often than people expect.

The workflow: reduce and alkylate any disulfides, digest with a specific protease — trypsin cleaving after lysine and arginine is the usual choice — separate the fragments by reverse-phase chromatography, and identify each by mass.

Reconciling gross mass to label claim

Sequence coverage is the headline quality metric. Anything below about ninety-five per cent leaves regions unexamined, and the unexamined regions are where a problem could sit undetected.

Peptide mapping is a compendial identity method for peptide and protein products and is specified in the relevant pharmacopoeial general chapters.

Ask for the coverage figure with any map. Without it the result is not interpretable.

Answering this needs to know whether a mass-neutral substitution is plausible for the sequence, since that is the case mapping is for.

The result is compared against the theoretical digest of the claimed sequence. A fragment at an unexpected mass localises a problem to a few residues; a missing expected fragment does the same from the other direction.

The underlying point is that for a short peptide, trypsin may produce too few fragments to be useful. Chymotrypsin, Glu-C or a combination gives better coverage on sequences with few basic residues.

Non-reduced peptide mapping is the accepted approach to confirming disulfide connectivity.

A missing expected fragment is as informative as an unexpected one.

The short version: enzymatic digestion, chromatographic separation of the fragments, mass identification of each, and a comparison against the theoretical map.

Disulfide scrambling gives an unchanged intact mass with different connectivity. Non-reduced mapping — digesting without reducing first — is how the correct pairings are confirmed.

A D-amino-acid substitution has an identical molecular weight to its L counterpart. It is invisible to intact mass, usually invisible to a routine gradient, and detectable by mapping combined with tandem fragmentation or by chiral analysis.

Commission it on a first lot from a new supplier, not on every lot.

edited 1 Jun 2026 by ekaterina_volk — corrected a unit error in the worked example

To be exact about it, this is the most informative single test available for a peptide identity question and it is rarely on a research-grade certificate.

Missed cleavages are normal and expected; a map with a moderate number of them is a normal map, not a failed one.

D-amino-acid substitutions being mass-identical is the structural reason intact mass cannot detect them and mapping plus fragmentation can.

Mapping is for mass-neutral problems. That is when it earns its cost.

The relevant limitation is that a mass-neutral substitution has the same molecular weight as the correct residue and can co-elute under a routine gradient.

Cost is the practical objection. Mapping costs several times a purity assay, which is why it belongs on a first lot from a new supplier rather than on every lot.

Coverage below about ninety-five per cent leaves real gaps, and the reported coverage figure should always accompany the conclusion.

Non-reduced mapping is how you confirm disulfide pairings.

edited 19 Mar 2026 by Dr_Yusuf_Adeyemi — added the citation requested in comments